JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
On Thursday, JMP Securities analysts maintained a "Market Outperform" rating on Addus HomeCare (NASDAQ:ADUS) with a steady price target of $150.00. The firm's assessment reflects confidence in the company's performance and growth potential, despite current market uncertainties. According to InvestingPro data, the stock currently trades well below analyst targets, with consensus high estimates reaching $160.00. The company maintains a "GREAT" overall financial health score of 3.45 out of 5.
Addus HomeCare's stock has recently been trading at approximately 11.1 times JMP Securities' 2025 adjusted EBITDA estimate. This valuation is below the company's 10-year median adjusted EBITDA multiple of 13.6 times. Additionally, Addus has historically traded at a median adjusted EBITDA multiple of 1.4 times that of the S&P 600 index over the last decade, a ratio it currently maintains.
The analysts acknowledge the impact of ongoing uncertainty surrounding potential Medicaid policy changes on the company's year-to-date trading multiple. Nonetheless, they remain optimistic about Addus HomeCare's prospects. The company plays a vital role in providing cost-effective care for elderly patients with complex needs, helping to avoid more expensive institutional care settings.
JMP Securities also notes the potential for growth through complementary clinical services and the possibility of further expansion through mergers and acquisitions. The $150 price target set by JMP Securities is based on applying a 14 times multiple to their 2026 adjusted EBITDA estimate for Addus HomeCare. This target reflects the firm's expectation for the company's continued financial growth and operational success.
In other recent news, Addus HomeCare Corporation has announced the upcoming retirement of its President and COO, W. Bradley Bickham, in March 2026, while CEO Dirk Allison's contract has been extended through March 2028. RBC Capital Markets adjusted its price target for Addus HomeCare to $133, maintaining an Outperform rating, citing the company's minimal exposure to potential Medicaid policy changes. KeyBanc Capital Markets reiterated an Overweight rating with a $150 price target, noting strong performance in Addus's Personal Care segment and positive impacts from a recent acquisition and rate increase in Illinois.
Stephens analyst Scott Fidel reduced the price target to $142, keeping an Overweight rating, while highlighting the company's commitment to revenue growth and a strong M&A pipeline. Raymond (NSE:RYMD) James also adjusted its target to $120 from $140, maintaining an Outperform rating due to ongoing concerns about potential Medicaid cuts. Despite these adjustments, analysts from each firm have expressed confidence in Addus HomeCare's strategic positioning and financial stability. The company's recent developments reflect a focus on leadership continuity and a strategic approach to navigating potential policy shifts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.